iPierian to advance lead Tau antibody, IPN007, for Alzheimer’s disease

True North to focus on Complement-mediated rare diseases, with lead drug candidate TNT009

SOUTH SAN FRANCISCO, CA — September 4, 2013 – iPierian, Inc., announced today that a new financing of $30 million has been secure…